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Abstract
Background: Genetic instability is known as a cause of oncogenesis. Though Rad18 is reported
to function in a post replication mismatch repair system, the relation between the status of Rad18
and human tumorigenesis has not been described so far.
Methods: Mutation analysis of 34 human cancer cell lines and 32 non small cell lung cancer
(NSCLC) tissues were performed by RT-PCR SSCP. Expression level of Rad18 was measured by
real time RT-PCR. Stable transfectant was constructed for in vitro study.
Results: No mutation was found in both cancer cell lines and NSCLC tissues. A single nucleotide
polymorphism (SNP) at codon 302 was detected in 51.5% of the cell lines and 62.5% of NSCLC
tissues. Interestingly, Rad18 was homozygously deleted in a pulmonary adenocarcinoma cell line
PC3. Furthermore, there was no difference in the expression level of wild type Rad18 and Rad18
with SNP. The growth, cell morphology, sensitivity to anti-cancer drugs and in vitro DNA repair
activity between wild type Rad18 and Rad18 with SNP revealed to have no difference in vitro.
Conclusion: Though the frequency of SNP was tended to be higher in NSCLC patients than
healthy volunteers (57.7%), as the difference was not significant, we have concluded that there is
no relation between Rad18 SNP and lung cancer development.
Background
Endogenous and environmental factors such as ultravio-
let, ionizing radiation, and numerous genotoxic chemi-
cals can cause DNA damage. These DNA lesions can be
repaired by various repair mechanisms [1]. For example,
the most frequent DNA lesions are efficiently removed by
pathways called base excision repair and nucleotide exci-
sion repair [2]. However, some unrepaired DNA lesions
can remain at replication because of limited capacity of
DNA repair systems. These lesions induce gaps in the
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newly synthesized strand. The gaps are filled by postrepli-
cation repair (PRR) system and this repair system is con-
served from yeast to mammalian cells [3,4]. In the yeast
Saccharomyces cerevisiae, genes belonging to the Rad6
epistasis group play an important role in the PRR pathway
[5]. In this pathway, Rad6 and Rad18 are the most impor-
tant genes. Rad6 is an ubiquitin-conjugating enzyme (E2)
and Rad18 is a single-stranded DNA binding protein and
has ubiquitin-ligase (E3) activity. Rad18 forms a specific
complex with Rad6 [6,7]. Human homolog of yeast Rad18
gene is mapped on chromosome 3p24-25 and it has been
shown that human Rad18 protein interacts with the
human homologs of the Rad6 protein (HHR6A and
HHR6B) and is involved in PRR [8,9]. Rad18 or Rad6
mutations cause higher sensitivity to various mutagens
[10]. Inactivation of Rad18 in mouse embryonic stem
cells leads to increasing sensitivity to various DNA-dam-
aging agents and to increasing sister-chromatic exchange.
Rad18 contributes to maintenance of genomic stability
through PRR [10]. However, the status of Rad18 in human
cancers is still unknown.
In the present study, we analyzed the expression and the
mutation of Rad18 in human cancer cell lines and NSCLC
tissues and also assessed whether there is some functional
difference due to the SNP of Rad18.
Methods
Cell lines and cell culture
Twenty-nine digestive carcinoma cell lines and five lung
carcinoma cell lines were used in this study. They com-
prised: 7 esophageal carcinoma cell lines (KYSE30,
KYSE140, TE1, TE9, TE10, TE12, TE13), 6 gastric carci-
noma cell lines (AGS, MKN1, MKN28, MKN45, NUGC3,
NUGC4), 9 colon carcinoma cell lines (Caco2, Colo201,
Colo205, DLD-1, HCT116, HT29, SW480, SW620,
WiDr), 7 pancreatic carcinoma cell lines (AsPC-1,
Capan1, Capan2, Panc1, SUIT-2, MiaPaCa2, Hs700T) and
5 lung carcinoma cell lines (A549, EBC1, LU99, PC3,
LCOK). Cell lines were cultured in recommended
medium supplemented with 10% fetal bovine serum
(Invitrogen) at 37°C in a humidified atmosphere of 5%
CO2 to 95% air.
Tissue samples
Non-small cell lung cancer samples were all surgically
resected in Kumamoto University Hospital (Kumamoto,
Japan) between 2005 and 2006. Informed consent was
performed to all patients. Only the samples with agree-
ment were used for further analysis. This study was
approved by the ethical committees of Kumamoto Uni-
versity Hospital. The following features were looked at:
sex, age, and pathological status (size, histological type, T
stage, lymph node metastasis, pStage). UICC Tumor-
Node-Metastasis Classification of Malignant Tumors [11]
was used to classify pathological status. For the controls,
peripheral white blood cells of 26 healthy volunteers were
collected.
RNA isolation
The frozen tissue samples were ground into powder in liq-
uid nitrogen. Total RNA of tissue samples and cell lines
were isolated by using Trizol reagent according to the
instruction manual (Invitrogen). Total RNA of leukocytes
obtained from 2 ml of peripheral blood was isolated by
using PURESCRIPT RNA Isolation Kit (Gentra systems).
RT-PCR
Five microgram of the total RNA was reverse transcribed
using oligo-dT primer and SuperScript III (Invitrogen)
according to the instruction manual. To confirm the
expression of Rad18, primer sets, 5'-TTC, ACA, AAA, GGA,
AGC, CGC, TG (forward) and 5'-TTA, CTG, AGG, TCA,
TAT, TAT, CTT, C (reverse) were used to amplify 310 bp
region of human Rad18 gene. PCR was carried out in a
condition of, 3 min at 94°C for initial denaturing, fol-
lowed by 35 cycles of amplification (94°C for 30 sec,
55°C for 30 sec, and 72°C for 30 sec) using GoTaq
(Promega). The amplified products were visualized on
1.2% agarose gel with ethidium bromide. GAPDH in the
same samples was also amplified using 25 cycles PCR
reaction as the internal control. The primer sets for
GAPDH is 5'-TGA, CCA, CAG, TCC, ATG, CCA, TC (for-
ward) and 5'-CCA, CCC, TGT, TGC, TGT, AGC, C
(reverse).
Fragment Southern
Genomic DNA from human breast cancer cell line MCF7
and lung carcinoma cell line PC3 were isolated using TRI-
ZOL according to the instruction manual. MCF7 was used
as positive control which was confirmed that this cell line
carry wild type Rad18 by RT-PCR direct sequencing (data
not shown). Ten microgram of genomic DNA were
digested by EcoRI or HindIII, electrophoresed on a 0.8%
agarose gel and transferred to a Hybond-NX membrane
(Amersham). Full length cDNA clone of Rad18  was
labeled using Psoralen-Biotin nonisotopic labeling kit
(BrightStar) and hybridized in PEG-SDS including 100
μg/ml Salmon sperm DNA at 65°C. Detection was done
using BioDetect nonisotopic detection kit (BrightStar)
according to the instruction manual. Membrane was
exposed to X-ray film and developed.
RT-PCR SSCP and direct sequencing
The primer sets for RT-PCR SSCP are shown in Table 1.
Each primer sets were designed to partially overlap the
next fragment with the length not more than 200 bp. Ten
primer sets cover the whole open reading frame of Rad18
gene and partially, 5' and 3' non coding lesion. PCR con-
dition is, 3 min at 94°C for initial denaturing, followed byJournal of Experimental & Clinical Cancer Research 2009, 28:106 http://www.jeccr.com/content/28/1/106
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35 cycles of amplification (94°C for 30 sec, 55°C for 30
sec, and 72°C for 30 sec). Each sample was denatured 5
min at 95°C and rapidly chilled on ice and loaded into
10% acrylamide gel including 5.4% glycerol for 6 hours at
120V using MiniProtean3 (BioRad) at 4°C. After electro-
phoreses, gels were stained using Silver Stain Plus Kit
according to the instruction manual (BioRad). All sam-
ples were screened for the presence of an aberrant band
compared with reference sample. Samples with abnormal
SSCP bands were directly sequenced by ABI 310. Cycle
sequencing was performed using Big-Dye Terminator v3.1
(Applied Biosystems). Sequencing analysis was done
using Sequencing Analysis Software (Applied Biosys-
tems).
Real time-PCR
Complimentary DNA, primers (10 pmol/μl) and Hyb-
probe probes (10 pmol/μl) were mixed in the LightCycler
FastStart DNA Master HybProbe Kit according to the
instruction manual (Roche Diagnostics). The primers and
probes are as follow: forward primer 5'-AGC, CTG, GGA,
AGC, ATC, ACA, TA, reverse primer 5'-CTG, TGG, CAA,
CCA, AAA, GTA,CG, Fluorescein probe 5'-CGC, TGA,
AAG, TGC, TGA, GAT, TGA, ACC, AAG, AA, LCRed640
probe 5'-CAA, GCG, TAA, TAG, GAA, TTA, ATG, TGG,
GCT, TTT, GC. PCR was carried out in the LightCycler Sys-
tem (Roche Diagnostics). Cycling conditions were 1 cycle
of 95°C for 10 minutes, 40 cycles of amplification (95°C
for 10 sec, 62°C for 10 sec, 72°C for 6 sec). The concen-
tration of GAPDH in the same samples was also quanti-
fied using the LightCycler-Primer Set (Nihon Gene). The
concentration of Rad18 was calculated as a ratio to the
amount of GAPDH detected.
Cloning of Rad18
Full length of Rad18 were amplified using primer sets, 5'-
ATT, TCG, AGT, GGT, GTT, GGA, GC (forward) and 5'-
TGG, TAC, CTG, TGT, GAA, ATG, TC (reverse). MCF7
cDNA was used as a template for wild type Rad18 and
EBC1 cDNA for SNP Rad18. Each product was ligated into
plasmid vector pcDNA3.1/V5-His-TOPO (Invitrogen).
Clones were sequenced using ABI310 and confirmed for
no PCR error.
Construction of stable transfectant
The PC3 cell line were transfected with either wild type
Rad18 or Rad18 SNP, using lipofectamine2000 (Invitro-
gen). Stable transfectants were selected for 4 weeks in Dul-
becco's Modified Eagle Medium (GIBCO) containing
G418 (400 μg/ml). We designated PC3 cell line with wild
type  Rad18  as PC3-WT Rad18  and PC3 cell line with
Rad18 SNP as PC3-SNP Rad18. PC3 cell line transfected
with pcDNA LacZ was also constructed as a control.
Cell growth and cell survival assay
Prior to the day before experiment, 5 × 104 of PC3-WT
Rad18 and PC3-SNP Rad18 cells were plated on a twelve-
well plate and incubated at 37°C. For growth assay, cells
were counted using hemocytometer at day 1, 3, 5, 7. For
cell survival assay, 5 × 104 cells per well were plated on a
twelve-well plate and indicated dose of cisplatin or CPT-
11 were added to the medium from day 1. Culture
medium containing cisplatin or CPT-11 was changed
daily. At day1, 3, 5, 7, the cells were washed twice with
PBS, trypsinized and stained by Trypan Blue solution. Liv-
ing cells were counted using hemocytometer. All measure-
ments were performed in triplicate.
Western Blotting
Whole cell lysate from PC3-LacZ, PC3-WT Rad18, and
PC3-SNP Rad18 were extracted using RIPA buffer includ-
ing protease inhibitor and phosphatase inhibitor. Twenty-
five micrograms of whole cell lysate were electrophoresed
in 10% SDS-PAGE gels and transferred on to PVDF mem-
brane. The membranes were blocked with 5% NFDM in
PBS/Tween20 (0.1%) at room temperature for 1 hour and
then were incubated with Rad18 first antibody (Santa
Cruz) for 1 hr at room temperature. The membrane was
then washed for 10 min 2× with PBS/Tween20 and then
were incubated with anti goat IgG second antibody (Santa
Cruz) for 45 min at room temperature. The membranes
were washed for 10 min 2× with PBS/Tween20 and for 10
Table 1: Primer sets for Rad 18 RT-PCR SSCP
No. Forward Reverse
1. CAG,CAT,CCT,CGG,GAG,CG AGG,ACA,GAA,ATT,TTC,TTA,TAC,AG
2. CCT,CAG,TGT,TCA,CAT,AAC,TAC GGA,GAT,TTG,GCT,GGT,GAC,TC
3. ACG,GAA,TCA,TCT,GCT,GCA,GT TTT,TAT,TTT,CTT,TTA,TCA,ACA,ACT,C
4. AGA,AAT,GAG,TGG,TTC,TAC,ATC,A GAC,AAT,CCA,CTT,TAGT,AAC,TTG
5. TCC,TGA,GCC,ACC,CTC,GAC ATC,AGA,GAG,CAA,ATT,ATA,TAC,AG
6. TTC,ACA,AAA,GGA,AGC,CGC,TG CTT,GAA,CTA,TTT,CAG,CAG,CTG
7. TAC,AAT,GCC,CAA,TGC,GAT,GC AAA,TTC,ACT,CTT,ATG,TTT,TTT,ACG
8. AGG,AAA,TAG,ATG,AAA,TCC,ACA,G TTA,CTG,AGG,TCA,TAT,TAT,CTT,C
9. AGC,TAT,CTT,CTG,TATG,CAT,GG CTC,TTA,TGA,TGT,CTG,AAC,TGG
10. CAG,AAT,CAG,ATT,CAT,GCA,ATA,G AAG,TCA,GCA,AAA,GCC,CAC,ATTJournal of Experimental & Clinical Cancer Research 2009, 28:106 http://www.jeccr.com/content/28/1/106
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The expression of Rad18 in human cancer cell lines Figure 1
The expression of Rad18 in human cancer cell lines. A: RT-PCR analysis of Rad18 in human cancer cell lines. A part of 
cell lines examined are present. The expression of Rad18 mRNA is observed in all cancer cell lines but PC3 (lane 24). Lane 1: 
KYSE30, 2: KYSE140, 3: TE1, 4: TE9, 5: TE10, 6: AGS, 7: MKN1, 8: MKN28, 9: NUGC3, 10: NUGC4, 11: Caco2, 12: Colo201, 
13: Colo205, 14: DLD-1, 15: HCT116, 16: AsPC-1, 17: Capan1, 18: Capan2, 19: Panc1, 20: SUIT-2, 21: A549, 22: EBC1, 23: 
LU99, 24: PC3, 25: LCOK. B: Fragment Southern of PC3 (lane 1) and MCF7 (lane 2). Rad18 is homozygously deleted in lung 
cancer cell line PC3.
SSCP analysis of human cancer cell line Figure 2
SSCP analysis of human cancer cell line. A: A part of SSCP of primer set 7 is present. The shifted abnormal band is 
pointed. B: The result of direct sequence of the shifted band. At codon 302, three different patterns were detected.
1        2        3       4        5        6        7       8   9       10
11      12      13     14       15      16     17     18      19 20
G  C A A  A T ᄼT AG    Aᄼ A
A
G A  AG    Aᄼ A G  C A T ᄼT G G  C A T ᄼT A  AG    Aᄼ A
A
BJournal of Experimental & Clinical Cancer Research 2009, 28:106 http://www.jeccr.com/content/28/1/106
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min 1× with PBS, incubated with ECL-Plus and then were
exposed to X-ray film and developed.
In vitro DNA repair assay
The activity of DNA repair was measured using RPA DNA
repair kit (Active Motif) according to the instruction man-
ual. PC3 cells were plated on a 6 well plate the day before
transfection. Three micro grams of LacZ, WT Rad18,
Rad18 SNP and the mixture of 1.5 μg each of WT and SNP
Rad18 plasmid were transfected to the cells as described
above. Forty hours after transfection, the cells were irradi-
ated by UV for 30 sec to damage DNA, and the nuclear
extract were purified 48 hr after transfection according to
the instruction manual. Various dose of the nuclear
extract (1 to 5 μg) were added to the 96 well plate pro-
vided by the kit and reacted. The absorbance was read
using kinetic microplate reader V-max (Molecular
Devices). All measurements were performed in triplicate.
Values of P < 0.05 were considered to be statistically sig-
nificant.
Results
Expression of Rad18 in human cancer cell lines
The expression of Rad18 gene in human cancer cell lines
was analyzed by RT-PCR. Except for PC3 cell line, Rad18
gene was expressed in all digestive and lung cancer cell
lines (Figure 1A). In PC3, no amplification was observed
also in PCR using PC3 genomic DNA as a template (data
not shown). Fragment southern blotting revealed that the
genomic lesion of Rad18 was homozygously deleted in
PC3 lung cancer cell line (Figure 1B).
Mutational analysis of Rad18 in cancer cell lines
RT-PCR SSCP of Rad18 in 33 cancer cell lines was ana-
lyzed by PCR-SSCP. Within the ten PCR fragment, only
PCR fragment No.7 showed abnormal band pattern in 17
cell lines (Figure 2A). Direct sequence of the abnormal
band revealed that all 17 cell lines carried a single nucle-
otide polymorphism (SNP) at the second letter of codon
302 (51.5%) and there were no other mutation (Figure
Rad18 expression level in lung cancer tissues Figure 3
Rad18 expression level in lung cancer tissues. Left: Expression level according to wild type and SNP. Right: Expression 
level according to the pattern of codon 302.
Table 2: Clinicopathological characteristics of NSCLC
WT (n = 12) SNP (n = 20)
N.S.
Age (years, mean ± SD) 70.6 ± 8.2 70.0 ± 8.8
N.S.
Sex
Male 9 12
Female 3 8
N.S.
Histological type
Squamous cell carcinoma 7 3
Adenocarcinoma 3 14
Others 2 3
N.S.
T stage
T1 4 13
T2 7 7
T3 1 0
N.S.
Lymph node metastasis
Positive 2 4
Negative 10 16
N.S.
pStage
IA 4 11
IB 3 5
IIA 0 2
IIB 5 2Journal of Experimental & Clinical Cancer Research 2009, 28:106 http://www.jeccr.com/content/28/1/106
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2B). This SNP was already reported in the SNP database.
Though there was no coding region mutation, as lung can-
cer cell line PC3 had a homozygous deletion in Rad18
genomic lesion and as Rad18 is mapped at chromosome
3p25 which is reported to have frequent LOH in lung can-
cer [12], we decided to analyze lung cancer tissue for
Rad18 mutation.
Mutation analysis of Rad18 in NSCLC tissues
The clinicopathological characteristics of examined
NSCLC patients are shown in Table 2. First we checked the
expression of Rad18 by RT-PCR The expression of Rad18
was observed in all 32 NSCLC tissues. RT-PCR SSCP
revealed that there was no mutation in Rad18  coding
region but the same SNP of codon 302. This SNP was
observed in 20 samples of 32 NSCLC tissues (62.5%) and
in 15 peripheral blood samples of 26 healthy volunteers
(57.7%). Though, the frequency of Rad18 SNP is tended
to be higher in NSCLC tissue than the healthy volunteers,
the difference was not significant. There was no difference
in other characters such as sex, histological type, T-stage,
lymph node metastasis or p-stage between WT and SNP
In vitro study of Rad18 WT and Rad18 SNP Figure 4
In vitro study of Rad18 WT and Rad18 SNP. A: Expression of introduced Rad18 assessed by RT-PCR (top) and Western 
blotting (bottom). Lane 1: PC3 + LacZ, 2: PC3-WT Rad18, 3: PC3-SNP Rad18. B: Cell morphology of the three cell lines. C: 
Growth assay of the three cell lines. D: Sensitivity to CDDP (left) and CPT-11 (right) in the three cell lines. E: Percent survival 
at day 7 for different dose of CDDP (left) and CPT-11 (right).
Table 3: Frequency of Rad18 Gln302Arg polymorphism
Lung cancer tissue Healthy volunteers
No. of samples 32 26
No. of polymorphism 20 (62.5%) 15 (55.7%) N.S.
Pattern of codon 302 N.S.
A (Gln) 12 (37.5%) 11 (42.3%)
A/G (Gln/Arg) 13 (40.7%) 7 (26.9%)
G (Arg) 7 (21.9%) 8 (30.8%)
Frequency
A (Gln) 37 (57.8%) 29 (55.8%) N.S.
G (Arg) 27 (42.2%) 23 (44.2%)Journal of Experimental & Clinical Cancer Research 2009, 28:106 http://www.jeccr.com/content/28/1/106
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(Table 2). In addition, there were no difference between
the three patterns of codon 302 and lung cancer develop-
ment (Table 3). Furthermore, Rad18 expression level was
also examined using light cycler (Fig 3). No difference was
observed between WT and SNP or between the three pat-
terns of codon 302.
In vitro study of Rad18 polymorphism
Though there was no Rad18 mutation in human cancer
cell line and NSCLC tissue examined except PC3, as
Rad18 functions as post-replication repair system, we
have examined whether there is any difference between
wild type Rad18 and Rad18 SNP in vitro. Using Rad18
null cell line PC3, wild type Rad18 or Rad18 SNP was
transfected. The expression of introduced Rad18 gene was
confirmed by RT-PCR and Western blotting (Fig 4A). The
cell morphology of these stable transfectant had no differ-
ence (Fig 4B). Additionally, there was no difference in
growth, sensitivity or survival rate against anti-cancer
drugs (CDDP or CPT-11) (Fig 4C, 5A, B). Furthermore,
the in vitro DNA repair showed that, when PC3 was trans-
fected with Rad18, the DNA repair was induced compared
to the control (LacZ transfected PC3). However, there was
no difference between the status of the codon 302 (A/A,
A/G, G/G) (Fig 5C).
Discussion
There is no doubt that genetic instability is one of the
main causes of cancer development. Genetic instability
can be divided in two. One is chromosomal instability
and the other is microsatellite instability (MSI). It is
reported that chromosomal instability is frequently found
in lung cancer but microsatelite instability is rare [13].
Though 60% of non small cell lung cancer has loss of het-
erozygosity (LOH) in 3p and it is suggested that several
tumor suppressor genes might be mapped in this region,
a clear relation between lung cancer development and a
single gene mutation has not been reported to date
[14,15]. Concerning microsatellite instability, using mic-
rosatellite markers located at 3p or targeting human mis-
match repair gene, hMLH1, has been analyzed [16,17].
They concluded that MSI is not frequently found in lung
cancer tissue or pleural effusion of lung cancer patients.
We focused on Rad18 which functions as a PRR system
and mapped on 3p25. Within the cell lines and lung can-
cer tissues that we examined, no Rad18  mutation was
detected but a homozygous deletion in PC3 (lung cancer
cell line). This result suggests that there might be no rela-
tion between Rad18 mutation and lung cancer develop-
ment. During the SSCP analysis, we found a SNP (Gln 302
Arg) which was relatively frequent in lung cancer tissues.
Drug sensitivity and repair function of Rad18 and the SNP Figure 5
Drug sensitivity and repair function of Rad18 and the SNP. A: Sensitivity to CDDP (left) and CPT-11 (right) in the 
three cell lines. B: Percent survival at day 7 for different dose of CDDP (left) and CPT-11 (right). C: DNA repair assay of LacZ, 
WT(A/A), hetero(A/G), SNP(G/G). The vertical axis is the amount of RPA protein which shows the activity of DNA repair 
function.Journal of Experimental & Clinical Cancer Research 2009, 28:106 http://www.jeccr.com/content/28/1/106
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Recently, a report that the same SNP of Rad18 is associ-
ated to the risk of lung cancer was published [18]. Differ-
ent to our study, this report was focused only on the SNP
and the mutation analysis of the entire Rad18 gene was
not evaluated. They used only genomic DNA extracted
from a formalin embedded lung cancer tissue which was
PCR amplified and checked only the status of codon 302
SNP and concluded that this SNP is the risk of lung cancer
development. The total number of the lung cancer sample
was quite large and the frequency of SNP and lung cancer
development was statistically different. If this single
nucleotide change (which changes the amino acid
sequence) is the cause of lung cancer, this is no more a
"polymorphism" but a "mutation". And if this nucleotide
change is a "mutation", there should be a difference in the
function between these two different proteins. Based on
the function of Rad18, as a key protein of PRR system, the
sensitivity to the DNA damaging reagents (cisplatin and
CPT-11) were examined according to the reports [19,20].
Furthermore, when Rad18 is null, it is reported that the
growth of the cells won't change but the abnormal mor-
phologies with nuclear segregation will occur [21,22].
Thus we investigated the differences of cell morphology,
cell growth and sensitivity to anti-drug agents. Unfortu-
nately, we could not find a difference from both clinical
samples and in vitro study. Furthermore, no difference
was observed in DNA repair function. Different to the
report, we used mRNA and analyzed the whole open read-
ing frame of Rad18 gene and also examined the expression
level, in vitro analysis.
Conclusion
From all these results, we came to a conclusion that, there
is no relation between Rad18 and lung cancer develop-
ment. Still there is a possibility that PRR system might be
involved in cancer development. As Rad18 interacts with
Rad6 and function as a ubiquitin enzyme to activate
PCNA, if these key proteins were involved in cancer, the
PRR system will not function and might lead to cancer
development. Further analysis of this system is required to
clear whether there is a relation between PRR and cancer
development.
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